Vical has acknowledged that both the monovalent and bivalent forms of its genital herpes vaccine candidate missed their primary endpoints in a Phase I/II trial, based on topline results.
The monovalent and bivalent vaccines—both formulated...
NEW YORK (TheStreet) -- Vical
shares are gaining, up 15.9% to $1.02, on heavy volume trading Tuesday after the biopharmaceutical company had coverage initiated with a "buy" rating by analysts at Roth Capital today.The San Diego-based company...
Vical Incorporated (NASDAQ: VICL) reported a narrower-than-expected loss for the first quarter on Friday.
The San Diego, California-based company posted a quarterly loss of $3.8 million, or $0.04 per share, versus a year-ago loss of $3.5...
Vical Incorporated (Nasdaq: VICL)
today announced the completion of enrollment in a Phase 1/2 trial of its
Vaxfectin^®-formulated therapeutic vaccine for herpes simplex virus type 2
(HSV-2), the predominant cause of recurrent genital herpes....
Vical, Inc. (VICL)
Q1 2014 Results Earnings Conference Call
May 01, 2014 12:00 PM ET
Tony Ramos - Chief Accounting Officer
Vijay Samant - President and CEO
Dr. Larry Smith - VP Vaccine Research
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Vical (VICL):